TargetMol

DSG3 Protein, Mouse, Recombinant (His)

Product Code:
 
TAR-TMPK-00726
Product Group:
 
Recombinant Proteins
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20°C
1 / 1
❮❯

Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-TMPK-00726-100ug100ugEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TMPK-00726-1mg1mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TMPK-00726-500ug500ugEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Show All

Further Information

Bioactivity:
To identify genes that could potentially serve as molecular therapeutic markers for human head and neck cancer (HNC),DSG3 is identified overexpressed in HNC, with the degree of overexpression associated with clinicopathologic features of the tumor. Inhibition of DSG3 significantly suppresses carcinogenic potential in cellular and in vivo animal studies. DSG3 is a potential molecular target in the development of adjuvant therapy for HNC. DSG3 Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 64.3 kDa and the accession number is O35902-1.
Molecular Weight:
64.3 kDa (predicted). Due to glycosylation, the protein migrates to 70-75 kDa based on Tris-Bis PAGE result.
Purity:
98%

References

1.Chen YJ, et al. DSG3 is overexpressed in head neck cancer and is a potential molecular target for inhibition of oncogenesis. Oncogene. 2007 Jan 18;26(3):467-76. doi: 10.1038/sj.onc.1209802. Epub 2006 Jul 3PMID: 16878157.